tiprankstipranks
Neurocrine Biosciences (NBIX)
NASDAQ:NBIX
Want to see NBIX full AI Analyst Report?

Neurocrine (NBIX) Stock Statistics & Valuation Metrics

1,629 Followers

Total Valuation

Neurocrine has a market cap or net worth of $18.18B. The enterprise value is $12.71K.
Market Cap$18.18B
Enterprise Value$12.71K

Share Statistics

Neurocrine has 100,549,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding100,549,980
Owned by Insiders1.14%
Owned by Institutions2.32%

Financial Efficiency

Neurocrine’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 10.80%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)10.80%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee1.43M
Profits Per Employee239.30K
Employee Count2,000
Asset Turnover0.62
Inventory Turnover0.76

Valuation Ratios

The current PE Ratio of Neurocrine is 27.2. Neurocrine’s PEG ratio is 0.71.
PE Ratio27.2
PS Ratio4.93
PB Ratio4.34
Price to Fair Value4.34
Price to FCF18.85
Price to Operating Cash Flow21.27
PEG Ratio0.71

Income Statement

In the last 12 months, Neurocrine had revenue of 2.86B and earned 478.60M in profits. Earnings per share was 4.81.
Revenue2.86B
Gross Profit2.81B
Operating Income619.10M
Pretax Income705.40M
Net Income478.60M
EBITDA666.60M
Earnings Per Share (EPS)4.81

Cash Flow

In the last 12 months, operating cash flow was 898.10M and capital expenditures -27.70M, giving a free cash flow of 870.40M billion.
Operating Cash Flow898.10M
Free Cash Flow870.40M
Free Cash Flow per Share8.66

Dividends & Yields

Neurocrine pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.63
52-Week Price Change44.66%
50-Day Moving Average167.11
200-Day Moving Average145.76
Relative Strength Index (RSI)58.30
Average Volume (3m)1.14M

Important Dates

Neurocrine upcoming earnings date is Nov 3, 2026, After Close (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateNov 3, 2026
Ex-Dividend Date

Financial Position

Neurocrine as a current ratio of 3.39, with Debt / Equity ratio of 11.92%
Current Ratio3.39
Quick Ratio3.30
Debt to Market Cap0.00
Net Debt to EBITDA-0.45
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Neurocrine has paid 226.80M in taxes.
Income Tax226.80M
Effective Tax Rate0.32

Enterprise Valuation

Neurocrine EV to EBITDA ratio is 20.72, with an EV/FCF ratio of 18.45.
EV to Sales4.83
EV to EBITDA20.72
EV to Free Cash Flow18.45
EV to Operating Cash Flow17.65

Balance Sheet

Neurocrine has $389.80M in cash and marketable securities with $401.80M in debt, giving a net cash position of -$12.00M billion.
Cash & Marketable Securities$389.80M
Total Debt$401.80M
Net Cash-$12.00M
Net Cash Per Share-$0.12
Tangible Book Value Per Share$32.69

Margins

Gross margin is 98.17%, with operating margin of 21.64%, and net profit margin of 16.73%.
Gross Margin98.17%
Operating Margin21.64%
Pretax Margin24.66%
Net Profit Margin16.73%
EBITDA Margin23.30%
EBIT Margin22.25%

Analyst Forecast

The average price target for Neurocrine is $210.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$210.13
Price Target Upside19.55% Upside
Analyst ConsensusStrong Buy
Analyst Count26
Revenue Growth Forecast28.59%
EPS Growth Forecast120.51%

Scores

Smart Score7
AI Score